Robert Hariri, MD, PhD

Happy to announce the completion of an important licensing agreement for the company: “CellxLife has secured an exclusive license for a potentially promising ovarian cancer therapy developed by Mayo Clinic This personalized cancer vaccine is designed to train the immune system to better recognize and fight cancer. Early clinical findings have shown: • ~40% of evaluable ovarian cancer patients remained cancer-free approaching 10 years • Favorable safety profile • Strong antigen-specific immune responses “We are encouraged by the ~40% 10-year cancer-free survival observed in early studies, and we believe the Phase II study may offer even greater promise,” said the CEO of CellxLife. This collaboration strengthens a growing pipeline of immune-based therapies and reflects an ongoing commitment to developing more effective, durable cancer treatments. #Biotech #Immunotherapy #CancerResearch #ClinicalTrials #CellTherapy#Cancer vaccine”

25

Lower levels of the anti-aging protein Klotho after surgery were strongly linked to higher inflammation and worse cognitive function in patients with postoperative cognitive dysfunction (POCD). This suggests Klotho could be a useful early biomarker—and possibly a treatment target—for predicting and improving cognitive outcomes after surgery. https://lnkd.in/gcZq_4v4

17

3 Comments

Back To Basics | Why Gene & Cell Therapy Is The Future Of Medicine With Mauricio Rodriguez & Dr. Vincent Giampapa The future of medicine is becoming increasingly cellular... and we here at Genetic LifeSpan™ are building towards it. We recently had the opportunity to sit down with Dr. Vincent Giampapa, a pioneer in regenerative and anti-aging medicine whose work has focused for decades on cellular restoration and longevity science. We’re incredibly excited about what we’re developing together through CelluSpan Therapies, the Gene & Cell Therapy Division of Genetic LifeSpan™, bringing advanced cellular science, regenerative medicine, and emerging gene and cell therapy strategies into a more personalized vision for the future of health.

20

$CELZ Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee. The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse events reported. https://lnkd.in/eUaAMXDq Communicated Disclaimer: https://lnkd.in/eHvpepDX

10

Confidence Backed by Commitment. Over the past year, Pluri Chairman Alejandro Weinstein has invested more than $17 million in the Company, increasing his ownership position to over 30% of Pluri’s outstanding shares. This investment reflects a strong belief in Pluri’s proprietary cell-based platform and its growing commercial opportunities. As Pluri advances its transition from platform development toward commercial execution, the Company is expanding its focus on longevity and preparing for increased commercial activity in the U.S., while also seeing strong inbound interest from potential product purchasers and technology collaborators. 🔗https://shorturl.at/nX2YY #Pluri #Longevity #Biotech #CellTherapy #RegenerativeMedicine #Exosomes #Commercialization #NASDAQ #PLUR

23

2 Comments

The era of traveling abroad for human Umbilical cord Wharton’s jelly and mesenchymal stromal stem cell treatments is ending. In the United States—within the beautiful states of Florida and Utah—physicians now have access to a higher standard. Regenerelle® WJ-MSC products are medical-grade, low-passage (P1–P4), and engineered to exceed the most stringent manufacturing standards—supporting physician-directed, experimental use in pain, wound care, and orthopedic applications. This is how regenerative medicine was meant to be delivered—safe, transparent, and uncompromising in quality.

31

3 Comments

A historic day for the future of regenerative biotherapeutics and regenerative aesthetics was unveiled at IMCAS, marking a powerful partnership between global nanotechnology pioneer Sesderma, its founder and innovator Dr. Gabriel Serrano, and the advanced exosome technology platform of Crowley Center for Regenerative Biotherapeutics & ATVentureCenter led by serial entrepreneur Michael C.

49

4 Comments

Celularity Inc. Celularity to Manufacture MuseCell Innovations Therapies in the US: https://lnkd.in/eSnYGXbd The initial program will use qualified perinatal starting materials and the licensed Dezawa Method, with product-specific testing and release criteria. #medicine #stemcells #regenerativemedicine #health #science

1

It is a pleasure to reintroduce SMSbiotech and its innovative approach to lung regeneration and the treatment of COPD at the Respiratory Innovation Summit (RIS), held under the auspices of the American Thoracic Society. The SMSbiotech team continues to advance its promising Phase 1b clinical trial in COPD patients, exploring the therapeutic potential of Small Mobile Stem (SMS) cells, smart drug, in tackling respiratory diseases that destroy the intricate architecture of the lungs. Roger Schechter, Medical Director of SMSbiotech, is presenting the company’s latest clinical progress and developments at the summit.

32

1 Comment